WUH: 07480-Randomized trial of COBRA PzF Stenting To Reduce Duration of Triple Therapy (COBRA-REDUCE)

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Symptomatic Ischemic
  • Age: Between 18 - 100 Years
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1. Subjects must be older than 18 years old
    2. Subjects must have schemic symptoms (stable or unstable angina or NSTEMI without thrombosis of the target lesion on coronary angiography) or evidence of myocardial ischemia
    3. Subjects must be receiving oral anticoagulation with coumadin derivatives or non –vitamin K oral anticoagulants
    4. Subjects must complete and sign the written, informed consent

You may not be eligible for this study if the following are true:

    1. Subjects with cardiogenic shock
    2. Subjects with target lesion located in left main trunk
    3. Subjects have bifurcation interventions with a planned 2 –stent strategy
    4. Subjects with vessel size too small for implantation of a 2.5 mm stent by visual estimation
    5. Subjects requiring staging PCI procedure within 6 months after the index procedure
    6. Subjects requiring DAPT for more than 2 weeks after the index procedure
    7. Subjects with malignancies or other co –morbid conditions with life expectancy less than 12 months or that may result in protocol non –compliance

If you are registered as a volunteer, please login to the dashboard to send referrals.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.